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1. Limitations of the guidelines
These guidelines have been prepared for dermatologists and 
other health care professionals on behalf of the Working Group 
of the Dermatological Society of South Africa and reflect 
the best data available at the time the report was prepared. 
Caution should be exercised in interpreting the data; the results 
of future studies may require alteration of the conclusions or 
recommendations in this report. It may be necessary or even 
desirable to depart from the guidelines in the interests of 
specific patients and special circumstances. These guidelines 
do not represent all the possible methods of management 
applicable to all patients, do not exclude any other reasonable 
methods, and will not ensure successful treatment in every 
situation. The unique circumstances of each patient should 
be taken into account by the responsible physician making 
decisions on any specific therapy. 
Just as adherence to guidelines may not constitute defence 
against a claim of negligence, so deviation from them should 
not necessarily be deemed negligent.
2. Introduction and methods
Psoriasis vulgaris is a chronic, relapsing, immune-mediated, 
potentially devastating disease, influenced by genetic and 
environmental factors, that can cause substantial morbidity and 
psychological stress and have a profound negative impact on 
patient quality of life.1,2
2.1 Incidence/prevalence
Approximately 2% of people worldwide have psoriasis, one-
third of whom have a moderate to severe form of the disease.3 
Age at onset is usually 16 - 22 years (‘early’) or 57 - 60 years 
(‘late’).4 The genetic background of these two types differs.5 
Males and females are affected in equal numbers.6
2.2 Genetic factors
Genetic predisposition to psoriasis follows a multifactorial 
pattern. Approximately 10 susceptibility genes (loci) have been 
identified. The most significant locus (PSORS1) lies within 
chromosome 6p21.3.7 Only about 10% of susceptibility gene 
carriers will develop the disease (low penetrance).5,8
2.3 Pathophysiology
Psoriasis is characterised by an abnormal regulation of the 
interaction between T cells and keratinocytes. The T-cell 
cytokine secretion profile resembles that of a Th-1 response.9
2.4 Environmental factors and triggers (Table I)
External factors (infections, streptococcal in particular, skin 
injuries, certain drugs) often trigger the onset of psoriasis.9 
Stress, smoking and excessive alcohol consumption may also 
be connected with the onset or worsening of the disease.9 
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Background. Psoriasis vulgaris is a chronic, relapsing, immune-
mediated, potentially devastating disease, influenced by 
genetic and environmental factors, that can cause substantial 
morbidity and psychological stress and have a profound 
negative impact on patient quality of life.
Objective. These guidelines for the management of psoriasis 
have been developed in an attempt to improve the outcomes 
of treatment of this condition in South Africa. Psoriasis has 
a major impact on the quality of life of sufferers, and it is 
expected that these guidelines, if implemented, will play a 
role in achieving improved outcome.
Scope. These guidelines were developed to address the 
diagnosis and treatment of psoriasis, of differing degrees 
of severity and in patients of all ages, by all health care 
professionals involved with its management.
Recommendations. All health care workers involved in 
the management of psoriasis should take note of these 
guidelines and try to implement them in clinical practice 
as far as possible. All treatment methods and procedures 
not substantiated by evidence from the literature should be 
discontinued and avoided to decrease the financial burden of 
psoriasis treatment.
Validation. These guidelines were developed through general 
consensus by a group of 8 South African dermatologists (the 
’Working Group’) sanctioned by the Dermatological Society 
of South Africa (DSSA), by adaptation for the South African 
situation of the current guidelines used in the USA, the UK, 
Germany, Canada and Finland. Draft documents were made 
available for comment to the dermatological community as a 
whole via the official website of the DSSA, and the guidelines 
were presented and discussed at the annual congress of 
the DSSA in 2008. All input from these sources, where 
appropriate, were then incorporated into these guidelines.
Guidelines sponsor. Schering-Plough initiated the project and 
sponsored the meetings of the working group and all costs 
generated by these meetings.
Plans for guideline revision. The field of biologicals and 
cytokine modulators is in a rapid phase of development, and 
revision of the scope and content of these guidelines will be 
ongoing as longer-term data emerge. 
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Drugs thought to precipitate or worsen psoriasis include 
alcohol, lithium, chloroquine, beta-adrenoreceptor blocking 
drugs, angiotensin-converting enzyme (ACE) inhibitors and 
non-steroidal anti-inflammatories (NSAIDs).9
3. Diagnosis
Although a biopsy may be required in atypical cases,10 the 
diagnosis of psoriasis is usually made clinically, without 
difficulty, based on the characteristic features.11
3.1 Clinical features
3.1.1 Skin
Characteristic cutaneous lesions facilitate diagnosis.
•    The most common lesions are plaques that are sharply 
demarcated, slightly elevated and covered with silvery 
scales. 
•     Gentle scraping of the scales reveals minute capillary 
bleeding points (Auspitz sign).
•     The elbows, knees, legs, lower back, scalp, and glans penis 
are the sites most often affected.
3.1.2 Nails
Nail involvement is common and can present as: 
•   pitting
•    separation of the distal nail plate from the nail bed 
(onycholysis)
•    pinkish-brown flecks beneath the nail plate (‘oil spots’) 
•   subungual hyperkeratosis. 
Acrodermatitis continua of Hallopeau is a painful, localised, 
pustular form of psoriasis which often leads to nail deformity.
3.1.3 Joints
Psoriasis may also affect the joints in 5 - 10% of cases.
3.2 Common types of psoriasis (Table II)
•    Plaque psoriasis accounts for 80 - 90% of cases.12 It is a 
stationary form of the disease with the lesions often covered 
with thick, silvery or waxy scales. Patients may have 
involvement ranging from only a few plaques to numerous 
lesions covering almost the entire body surface.13
•    Guttate psoriasis is often triggered by tonsillitis. Its small 
lesions are widely distributed over the body.
•    Flexural (inverse) psoriasis is localised to the main skin 
folds (genitocrural area, navel, axillae, submammary 
region).
•    Pustular psoriasis may be generalised or localised to the 
palms and soles. 
•    Erythrodermic psoriasis is a generalised form of the disease 
and is most refractory to treatment.
3.3 Differential diagnosis (Table III)
3.3.1 Scalp 
•    Seborrhoeic dermatitis. The flakes are thinner and 
‘greasier’, and the condition responds better to treatment. 
It is often difficult to differentiate seborrhoeic dermatitis 
from psoriasis unless other skin areas offer additional 
information.
•    Fungal infection of the scalp mostly affects children. This 
diagnosis can be excluded by microscopy and a negative 
culture for fungi.
•    Neurodermatitis of the neck (lichen simplex nuchae) is 
characterised by an isolated, lichenified, pruritic plaque 
covered with thin scales.
3.3.2 Flexures
•    Seborrhoeic dermatitis may resemble flexural psoriasis. 
Other skin areas should be examined.
Table I. Factors that trigger, precipitate or worsen psoriasis9
External factors    Lifestyle factors    Medications
Infections (esp. streptococcal)   Stress     Lithium 
Skin injuries    Smoking     Chloroquine
     Excessive alcohol consumption  Beta-adrenoreceptor blockers
          ACE inhibitors
Table III. Differential diagnosis of psoriasis 
Scalp
Seborrhoeic dermatitis
Fungal infection
Neurodermatitis
Flexures
Seborrhoeic dermatitis
Fungal infection
Candidiasis
Erythrasma
Hands and feet
Hyperkeratotic eczema
Fungal infection
Table II. Common types of cutaneous psoriasis and their 
distribution 
Type   Distribution/description
Plaque psoriasis   Stationary form of the disease
   Thick, silvery or waxy scales 
   Localised or generalised
Guttate psoriasis  Small ‘teardrop’ lesions, wide
   distribution over the body
Flexural (inverse) psoriasis  Main skinfolds (genitocrural area, 
   navel, axillae, submammary   
   region).
Pustular psoriasis  Generalised or localised to the
   palms and soles
Erythrodermic psoriasis Generalised
(refractory to treatment)
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•    Fungal infection (tineas) may resemble psoriasis; however, 
it usually heals in the centre and expands peripherally. 
Microscopy and fungal culture are diagnostic.
•    Candidiasis is not often seen in young and middle-aged 
patients. It presents as a moist area of erythema and 
maceration with outlying ‘satellite lesions’.
•    Erythrasma is a macular brown area with few symptoms, 
most often found in the axillae or groin. It is caused by an 
overgrowth of diphtheroids, which are part of the normal 
skin flora. These areas fluoresce coral-pink under Wood’s 
light.
3.3.3 Hands, feet
•    Hyperkeratotic eczema of the palms and palmoplantar 
pustulosis may be difficult to differentiate from psoriasis. 
The entire skin should be examined.
•    Fungal infection can easily be diagnosed by microscopic 
examination and culture.
4. Classification
Classification of psoriasis is based on the type of psoriasis (see 
above) and on disease severity, which is described as mild, 
moderate or severe. 
Severity is a qualitative decision, hinging on the measures 
of disease activity, resistance to prior therapy and psychosocial 
considerations.  Various measures of severity exist and are 
listed in Table IV. 
A 75% improvement in the PASI score (PASI-75) is 
predominantly used to document the effectiveness of 
individual therapies in clinical trials of patients with extensive 
psoriasis.13 A DLQI of 10 or more correlates well with severe 
disease requiring admission, phototherapy or second-line 
therapy, and an improvement in DLQI of 5 or more points is 
considered a worthwhile criterion for response. 
One should keep in mind that marked cross-cultural 
inequivalence exists in these tools to measure quality of life 
impact;12 no tools for this purpose have been developed 
specifically for South African cultural groups. 
4.1 Quality of life
Psoriasis may profoundly affect all aspects of patients' social 
and personal lives (including their work). The impact of 
psoriasis on a patient is not directly related to the overall 
area affected, or to other parameters of disease activity 
such as redness or thickness of plaques, but more to the site 
distribution and the attitude of the patient. It is important to 
be able to measure the handicap caused by psoriasis for use 
in clinical trials, for audit purposes and to aid clinical decision 
taking.
4.2 How do we define the severity of psoriasis?
All existing disease severity assessment tools are imperfect 
and most require some training to complete. There is currently 
no universally accepted definition of what constitutes mild, 
moderate and severe psoriasis, nor can there be a concise 
and clinically meaningful definition given the broad clinical 
spectrum. 
BSA of involvement is not an adequate parameter. The PASI 
score, severity of individual lesions, localisation of lesions, 
symptoms, functional impairment, effect on quality of life 
of the patient, and response to and side-effects of previous 
treatment also have to be taken into account. 
The Working Group considered the existing definitions14-18 
of moderate to severe psoriasis and concluded that the burden 
psoriasis presents to the patient is often underestimated by 
physicians and regulatory authorities, as is the extent to which 
current treatments influence patients’ quality of life. 
The Working Group made recommendations for the defining 
criteria of psoriasis severity (Table V).
5. Referral (Table VI)
Referral to a dermatologist should be considered in the 
following instances:
•    Patients with extensive disease who need secondary care 
treatments. The dermatologist should also be involved in 
the care of difficult cases where the site or unresponsiveness 
of the rash are important factors. 
•    Diagnostic uncertainty. 
•    Request for further counselling and/or education, including 
demonstration of topical treatment. 
•    Failure of appropriately used topical treatment for a 
reasonable time (e.g. 2 - 3 months). 
•    Extensive disease, if unresponsive to initial therapy or 
difficult to self-manage. 
•    Need for increasing amounts or potencies of topical 
corticosteroids. 
•    Involvement of sites which are difficult to treat, e.g. face, 
palms and soles, genitalia, if unresponsive to initial therapy. 
•    Need for systemic therapy, phototherapy (e.g. guttate 
psoriasis), day treatment or inpatient admission. 
•    Generalised erythrodermic or generalised pustular psoriasis 
(emergency referral is indicated), or acute unstable psoriasis 
(urgent referral may be justified). 
•    Adverse reactions to topical treatment. 
•    Occupational disability or excessive time off work or school.
5.1 Content of the referral letter (Table VII)
The referral letter should include:
•    The reason for referral and what is hoped to be gained from 
the consultation (the consultant should try to address these 
issues in reply). 
•    The patient's present therapy (if any), its duration and the 
quantity being used. 
Table IV. Measures of psoriasis severity14
•    Psoriasis Area and Severity Index (PASI). The PASI is a 
measure of overall psoriasis severity and coverage that 
assesses body surface area, erythema, induration and 
scaling13
•   Body surface area (BSA) affected
•   Overall Lesion Severity Scale (OLS)
•   Physician's Global Assessment (PGA)
•   Health-related Quality of Life (HRQL)
•   Dermatology Life Quality Index (DLQI)
Guideline
April 2010, Vol. 100, No. 4  SAMJ260
•    Information on previous therapy, including responses or 
side-effects (a treatment could be mistakenly recorded as 
ineffective when the real problem was under-treatment or 
incorrect use of the prescribed treatment, or discontinued 
as unsuitable when transient side-effects could have been 
overcome had more advice been given).
•    Any relevant background information, including the 
patient's general health and current medication. 
•    The patient’s home circumstances. This is important as the 
patient’s ability to apply topical therapies at affected sites 
may be compromised, affecting treatment choice. 
6. What is the current treatment 
paradigm?
Treatment paradigms are conventionally based on the 
morphological type and severity of psoriasis. 
For moderate to severe plaque psoriasis, many practitioners 
believe in the traditional strategy, commonly depicted as a 
stepwise paradigm starting with topical agents followed by 
phototherapy and then systemic agents.10,11,16 The physician 
must deem a step ineffective before progressing to the next 
step. 
First-line systemic treatment may be indicated if topical 
therapy is impractical.1 More recent versions of the stepwise 
model (Table VIII) incorporate biologicals into the same 
category as other systemic agents and recommend that they 
be considered as first-line therapies alongside conventional 
systemic agents.12 
6.1 Shortcomings of the conventional treatment 
paradigm
The Working Group considered both the shortcomings of the 
stepwise treatment paradigm and potential areas for improving 
the current recommendations for the care of patients, and 
concluded that there was an unmet need in the management of 
moderate to severe psoriasis.
The therapy(ies) selected by the patient with the advice of 
their physician must take into account the following aspects:
Disease 
•   The type of psoriasis present in the patient
•    Location of lesions: face, ears, hands, feet, genitalia and 
intertriginous areas, scalp, nails, trunk, extremities
•    Severity of the lesions: thickness, redness, scaling 
•   Symptoms: pain, pruritus, other
•   Extent of disease, BSA estimates; PASI score
•   Joint involvement.
Patient 
•   Age of the patient
•    Quality of life considerations: ability to perform daily 
activities, employability, interpersonal relationships
•    Co-morbid disease/disease states including childbearing 
potential, pregnancy, desire to impregnate, liver disease, 
hepatitis C or HIV infection, hypertension, metabolic 
syndrome and alcohol intake.
Treatment
•   Response to previous therapies
•    Accessibility to dermatologist, hospital, ultraviolet (UV) 
light facilities 
•    Therapies available to treating physician, and physician 
preferences and experience.
Table V. Defining criteria of psoriasis severity
Mild psoriasis     Moderate to severe psoriasis
Generally <5% of BSA affected   ≥10% BSA affected
Disease does not alter the quality of life of the patient <10% BSA affected with very thick, red and/or scaly plaques
Effective treatment has no serious side-effects  <10% BSA affected and resistant to topical therapy
      Psoriasis causing a significant impact on quality of life:
         Functional impairment involving hands or feet
         Marked pruritus
         Marked discomfort
          Psoriasis in certain locations significantly impacting on quality of life and 
self-esteem irrespective of % BSA affected
Table VI. Criteria for referral to a dermatologist
•  Extensive disease 
•  Need for systemic treatment or phototherapy
•  Diagnostic uncertainty
•  Further counselling/education
•   Failure of topical therapy (2 - 3 months)/adverse reactions to 
topical therapy
•  Increased amount or potencies of topical corticosteroids
•  Difficult-to-treat areas
•  Need for day treatment or inpatient admission
•   Generalised erythrodermic/pustular psoriasis (emergency 
referral)
•  Acute unstable psoriasis (urgent referral)
•  Occupational/school absence or disability
Table VII. Content of the referral letter 
•   Reason for referral
•   Current therapy
•   Previous therapy (responses or side-effects)
•   General medical health
•   Any other current medication
•   Home circumstances
Table VIII. Conventional step-wise treatment paradigm
Step 1  Step 2  Step 3
Topical agents Phototherapy Systemic agents
    Biologicals
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Economic 
•    Economic factors relating to therapy options, e.g. cost/
benefit ratios, potential for third-party insurers to approve 
the plan for treatment.
6.2 What are the unmet needs for treatment of 
patients with moderate to severe psoriasis? (Table 
IX)
There is a need for improved education on the negative 
physical and HRQL impact on patients and physicians (e.g. 
physical, emotional and social impact). To help patients come 
to terms with what is, for many, a lifelong condition, great 
efforts should be made to improve communication during 
consultations and to educate patients.
Patients should have a plan of management, including 
the therapeutic options for the treatment of their psoriasis at 
each site involved, and verbal and written information on the 
probable benefits and possible side-effects of each therapy, 
enabling them to make an informed decision about the 
treatment. 
Ideally practical demonstrations of the application of 
treatment should be offered by appropriately trained members 
of a primary health care team.
An introduction to patient support groups may be helpful. 
7. Current therapeutic options
Therapeutic options for psoriasis range from topical treatment 
to phototherapy and systemic agents, including biologicals 
(Fig. 1). The choice of therapy is determined in part by the 
severity of the illness. Each of these therapeutic options will 
be discussed in depth, highlighting the current evidence 
supporting their efficacy and safety, their practicality for 
patient and physician, and general recommendations for their 
use.13,32,33
The various therapeutic options will now be discussed by 
treatment class. This section of the guidelines has been adapted 
with written permission from the authors of the German 
Guidelines for Psoriasis.32,33
7.1 Topical therapy
Evidence has shown that the selection of treatment for patients 
with psoriasis vulgaris is more commonly based on traditional 
concepts than evidence-based data on the efficacy of various 
therapeutic options. This section of the guidelines provides 
explanations of available topical treatments, as well as different 
photo- and photochemical therapies, for psoriasis. They 
are based on the German evidence-based guidelines for the 
treatment of psoriasis vulgaris, modified and adapted where 
applicable for the South African context.32,33
The aim of the guideline is to provide a tool that enables the 
physician to select an appropriate treatment for each individual 
patient on the basis of evidence-based studies rather than 
personal experience or traditional therapeutic concepts. For 
this purpose a total of 6 224 publications were evaluated and 
data used where appropriate.
The currently available topical treatments are summarised 
in Table X, which provides an overview of the evaluation of 
therapeutic options. The various therapeutic options are then 
discussed in more detail.
7.1.1 Topical corticosteroids (Table XI)33
General assessment
With the application of potent corticosteroids (betamethasone 
diproprionate, twice daily), 46 - 56% of patients show a clear 
improvement or a complete clearing of skin lesions. Therapy 
with very potent corticosteroids (clobetasol-17-propionate, 
twice daily) demonstrated similar results in 68 - 89% of patients 
in most studies.
Topical corticosteroids demonstrate good to very good 
efficacy in the treatment of mild to moderate psoriasis. 
Combination with salicylic acid enhances the therapeutic 
effect. Combination with other systemic or topical therapies 
also results in improved rates of remission. The most common 
combination is with topical vitamin D3 derivates or tar.
There are no severe adverse drug reactions in the induction 
phase. Care must be taken regarding development of 
typical adverse corticosteroid effects such as skin atrophy 
or telangiectasia in cases of longer use and in particularly 
sensitive areas. The practicality for physicians and patients is 
good.
7.1.2 Coal tar (Table XII)33
General assessment
Since only one monotherapy study was evaluated (with 3 
patients), it is not possible to make a clear statement about the 
efficacy of monotherapy (level of evidence (LE) 4). Coal tar has 
been used in clinical studies in combination with phototherapy.
In combination therapy with UV light, a reduction of 
the PASI by about 75% was achieved in 45 - 80% of study 
participants after 15 - 20 applications. The additional effect of 
coal tar in combination therapy with UV compared with UV 
therapy alone has not been proven.
Therapeutic recommendation
•    Therapy with topical corticosteroids is highly 
recommended for mild to moderate psoriasis vulgaris as 
a combination therapy with systemic therapies or other 
topical therapies. 
•    The selection of the class of corticosteroids must be 
adjusted for the specific skin area to be treated. 
•   Long-term use must take safety aspects into account.
Table IX. Unmet needs of treatment
•   Long-term sustainable relief19-21
•   Safe and convenient control11,22-27
•   Individualised treatment tailored to patients’ needs1,19,28
•   Patient satisfaction with current therapy29
•   Increased recognition of HRQL issues30,31
•   Improved education on psoriasis
Guideline
April 2010, Vol. 100, No. 4  SAMJ262
7.1.3 Dithranol (Table XIII)33
General assessment
The results of the studies assessed showed total remission 
(PASI reduction 100%) in 30 - 70% of patients and partial 
remission (PASI reduction 75%) in 26 - 100% after 5 - 8 weeks 
of treatment (LE 2). The efficacy can be improved further if 
either calcipotriol creams or UVB phototherapy are combined 
with dithranol.
Therapeutic recommendation
•    Although the efficacy of coal tar in the treatment of 
psoriasis as monotherapy has not been demonstrated, it 
is an inexpensive alternative in some patients. 
•    It can also be used in combination with phototherapy 
(UVB).
Therapeutic recommendation
•    Short-duration therapy should be given preference 
because it is more practical.
•    In hospitalised patients, classic dithranol therapy with 
twice-daily application without immediate rinsing can 
easily be performed. 
•    The therapy should be performed for 4 weeks and 
conditionally recommended as an outpatient treatment 
for 4 - 8 weeks. 
•    Maintenance or long-term therapy with dithranol is not 
practical and offers no advantages. 
•    In the treatment of severe forms of psoriasis, combination 
treatment with phototherapy or other topical 
preparations (calcipotriol) is recommended because of 
the improved response rate.
 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Overview of current therapeutic options in psoriasis (adapted with written 
permission from the German Guidelines for Psoriasis32,33). *Products not currently 
registered in South Africa. 
 
 
 
 
 
 
 
 
Mild 
Moderate 
Severe 
Topical  
therapy 
Systemic 
therapy 
Phototherapy 
Traditional 
systemic 
therapy 
Biologicals 
Corticosteroids (Diprosone®; Dermovate®; Dovate® 
Xenovate®) 
Coal tar (Linotar® 1 gel; Polytar® Plus) 
Dithranol (Anthranol®) 
Tazarotene (Zorak®) 
Vitamin D3 analogues (Dovonex
®; Rocaltrol®) 
Tacrolimus (Protopic®) 
 
Combinations:  
Corticosteroids plus salicylic acid (Diprosalic®) 
Corticosteroids plus vitamin D3 analogues (Dovobet
®)  
UVB 
PUVA 
Acitretin (Neotigason®) 
Ciclosporin (Sandimmun®) 
Methotrexate (P&U 
Methotrexate®; Emthexate®; 
Abitrexate®) 
T-cell targeted biologicals: 
Alefacept (Amevive®)* 
Efalizumab (Raptiva®)* 
 
Cytokine modulators: 
TNF- blockers 
Adalimumab (Humira®) 
Etanercept (Enbrel®) 
Infliximab (Revellex®) 
IL-12/23 monoclonal 
antibody 
Ustekinemab* 
Fig. 1. Overview of current therapeutic options in psoriasis (adapted with written permission from the German Guidelines for Psoriasis32,33). *Products not 
currently registered in South Africa.
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Table X. Overview of topical monotherapy33
 Corticosteroids        ++++*               1       +++                 +    ++        +++           +++
Dithranol 
   
        ++               2      ++       Not indicated 
   +†          +†  
          +++    
      
   - ‡         - ‡
Tazarotene            ++               2      ++                ++     ++         ++            ++
Vitamin D3           +++               1     +++               +++     ++        +++            ++
analogues 
 
Global consideration:   poor ←-----------------------------------------→ good
         -          +/-         +         ++         +++       ++++
Efficacy. The evaluation of the efficacy column reflects the percentage of patients who achieved a reduction in the baseline Psoriasis Area 
and Severity Index (PASI) of ≥75% (++++ approx. 60%; +++ approx. 45%; ++ approx. 30%; + approx. 15%; +/- approx. 10%; - not defined). 
The evidence level applies only to the estimate of efficacy.
Safety/tolerance on induction therapy or maintenance therapy. This refers to the risk of occurrence of severe adverse drug reactions or the 
probability of adverse drug reactions that would result in the discontinuation of therapy.
Practicality (patient). This evaluation analyses the effort involved in handling and administrating the treatment regimen by the patient.
Practicality (physician). This aspect considers the amount of work (documentation, explanation, monitoring), personnel and equipment 
needs, time for physician/patient interaction, remuneration of therapeutic measures, invoicing difficulties/risk of recourse claims from 
the health insurance companies.
Cost/benefit. Consideration for the costs of an induction therapy, or a maintenance therapy.
The evaluations of safety/tolerance in induction therapy or maintenance therapy as well as practicality for the physician or patient and 
the cost/benefit were performed using a scale ranging from poor (-) to good (++++). The gradation between these two extremes was made 
based on expert opinion and unsystematic literature search. A level of evidence was not given for these evaluations, since no systematic 
literature review was performed.
*Potent (e.g. betamethasone) or very potent corticosteroid (e.g. clobetasol), also valid for fixed combinations (vitamin D plus potent corticosteroids).
†Inpatient.
‡Outpatient.
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Table XI. Summary, topical corticosteroids    
Recommended control parameters    None
Recommended initial dosage     Once or twice daily
Recommended maintenance dosage    Gradual reduction following onset of effect
Expected beginning of clinical effect    After 1 - 2 weeks
Response rate       Betamethasone dipropionate, twice daily: marked improvement or 
clearance of the skin lesions in 46 - 56% patients after 4 weeks  
(LE 1) 
Important contraindications     Skin infections, rosacea, peri-oral dermatitis
Important adverse reactions      Skin infections, peri-oral dermatitis, skin atrophy, hypertrichosis, 
striae
Important drug interactions     None
LE = level of evidence.
263
Guideline
April 2010, Vol. 100, No. 4  SAMJ
Dithranol, one of the oldest topical therapeutics for psoriasis, 
is still a treatment for mild to moderate psoriasis as outpatient 
monotherapy and as part of combination therapies for 
moderate psoriasis in hospitalised and day clinic patients.
The therapy is very safe. Although skin irritation, burning, 
erythema and intermittent brown discolorations are observed, 
there are no systemic adverse reactions. The practicality 
is limited in outpatient use, due to these events, and the 
introduction of newer topical agents. However, the practicality 
for the physician, especially when treating inpatients, and the 
cost/benefit ratio are positive. 
7.1.4 Tazarotene (Table XIV)33
General assessment
After daily treatment with tazarotene 0.1%, approximately 50% 
of patients showed at least a 50% improvement of the skin 
lesions after about 12 weeks of treatment (LE 2). Therapeutic 
success and reduction of the frequent skin irritations can 
be optimised with a combination of tazarotene and topical 
corticosteroids. There are no severe adverse reactions. 
However, contact with healthy skin should be avoided to 
prevent skin irritation.
7.1.5 Vitamin D3 analogues (Table XV)33
General assessment
The majority of available data are on calcipotriol. After 
D3-analogue treatment of mild to moderate psoriasis, 30 - 50% 
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Table XIII. Summary, dithranol    
Recommended control parameters    Intensity of irritation
Recommended initial dosage      Begin with 0.5% preparation for long-term therapy or 1% for short-
contact therapy, then increase if tolerated
Recommended maintenance dosage    Not recommended for maintenance therapy
Expected beginning of clinical effect    After 2 - 3 weeks
Response rate       Marked improvement or clearance of skin lesions in 30 - 50% of 
patients (LE 2)
Important contraindications     Acute, erythrodermic forms of psoriasis; pustular psoriasis
Important adverse reactions     Burning and reddening of the skin in >10%
Important drug interactions     -
Table XII. Summary, coal tar
Recommended control parameters     After long-term application/application on large areas: if needed 
clinical controls for potential development of skin carcinoma
Recommended initial dosage     5 - 20% ointment preparations or gels for local therapy, once daily
Recommended maintenance dosage    No long-term application (max. 4 weeks)
Expected beginning of clinical effect     After 4 - 8 weeks, efficacy improves in combination with UV 
application
Response rate       There are insufficient data available on the response rate as a 
monotherapy (LE 4)
        Combination with topical steroids (10 - 50%) and salicylic acid 
enhances efficacy
Important contraindications     Pregnancy and breastfeeding
Important adverse reactions      Colour, odour, carcinogenic risk, phototoxicity (which is part of the 
desired effect)
Important drug interactions     Not known with topical use
Table XIV. Summary, tazarotene
Recommended control parameters    Check development of skin irritation
Recommended initial dosage      Begin with one treatment daily of tazarotene gel 0.05% in the 
evening for approximately 1 - 2 weeks
Recommended maintenance dosage    If necessary continue for 1 - 2 weeks with tazarotene gel 0.1%
Expected beginning of clinical effect    After 1 - 2 weeks
Response rate       After 12 weeks’ therapy with 0.1% tazarotene gel there was at least 
50% improvement in approximately 50% of patients (LE 2)
Important contraindications     Pregnancy and breastfeeding
Important adverse reactions     Pruritus, burning sensation of skin, erythema, irritation
Important drug interactions      Avoid concomitant use of preparations with irritating and drying 
properties
Therapeutic recommendation
•    The topical application of tazarotene is recommended for 
the treatment of mild to moderate psoriasis. 
•    An application of tazarotene in the evening in 
combination with a corticosteroid in the morning is 
recommended as a combination therapy to reduce 
irritation and increase efficacy.
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of patients showed a marked improvement or clearance of the 
skin lesions within a few weeks (LE 1).
Efficacy and tolerance can be improved further if the 
vitamin D3 analogue is combined with topical corticosteroids 
during the initial therapy. In the treatment of severely 
affected patients, topical therapy with vitamin D3 analogues 
demonstrated synergistic effects with UV phototherapy and 
systemic ciclosporin therapy.
The topical vitamin D3 analogues are generally well tolerated 
and practical for the physician and the patient. Temporary 
skin irritation may limit use, especially on the face or the 
intertriginous areas.
7.1.6 Tacrolimus ointment34
•    Tacrolimus ointment is effective for facial and intertriginous 
psoriasis.
•    Topical tacrolimus appears relatively ineffective for 
the treatment of plaque-type psoriasis owing to poor 
penetration through the plaque.
•    A thin layer of cream is applied to the affected areas twice 
a day.
•    It is well tolerated and the only adverse effect is occasional 
pruritus in the treated areas.
•    Topical tacrolimus offers the potential for anti-inflammatory 
effect without the atrophy or local side-effects associated 
with the use of topical corticosteroids.
•    It is therefore recommended for use in intertriginous or 
facial psoriasis. 
7.2 Phototherapy (Tables XVI and XVII)
General assessment
About three-quarters of all patients treated with phototherapy 
attained at least a 75% PASI score reduction after 4 - 6 weeks, 
and clearance was frequently achieved (LE 2). Phototherapy 
represents a safe and very effective modality for the treatment 
of moderate to severe forms of psoriasis. The onset of the 
clinical effect is within 2 weeks.
Of the unwanted side-effects, UV erythema from 
overexposure is by far the most common and is frequently 
observed. With repeated or long-term application, the 
consequences of high, cumulative UV dosages (i.e. premature 
ageing of the skin) must be taken into consideration. In 
addition, carcinogenic risk is associated with oral psoralen + 
UVA photochemotherapy (PUVA) and is probable for local 
PUVA and UVB.
The practicality of the therapy is limited as a result of the 
spatial, financial and human aspects, as well as the amount of 
time required by both the physician and the patient. From the 
perspective of the cost-bearing institution, phototherapy has 
a good cost-benefit ratio. However, the potentially significant 
costs and time required of the patient must be noted.
Instructions for application
Pre-treatment
•    The attending physician has to perform a complete skin 
Table XV. Summary, vitamin D3 analogues   
Recommended control parameters    Monitor for skin irritation
Recommended initial dosage      Calcipotriol: Once or twice daily to affected locations, up to a 
maximum of 30% of body surface 
        Tacalcitol: Once daily to affected locations, up to a maximum of 
20% of body surface
        Calcitriol: Twice daily to affected locations, up to a maximum of 
35% of body surface
Recommended maintenance dosage     Calcipotriol: Once or twice daily, up to 100 g/wk for up to 1 year
        Tacalcitol: Once daily for 8 weeks, for up to 18 months, on a 
maximum of 15% of body surface with up to 3.5 g/d
        Calcitriol: Insufficient experience with application for more than 6 
weeks
Expected beginning of clinical effect    After 1 - 2 weeks
Response rate       Between 30% and 50% of patients demonstrated a marked 
improvement or clearance of the lesions after 4 - 6 weeks (LE 1)
Important contraindications      Diseases with abnormal calcium metabolism, severe liver and renal 
diseases
Important adverse reactions     Skin irritation (reddening, itching, burning)
Important drug interactions      Drugs that elevate the calcium levels (e.g. thiazide diuretics), 
no concomitant application of topical salicylic acid preparations 
(inactivation)
Other        Exposure to UV light results in inactivation of the vitamin D3 
analogues
Therapeutic recommendation
•    Vitamin D3 analogues are the treatment of choice for 
maintenance therapy in mild to moderate psoriasis. 
•    On the basis of the extensive study data and superior 
efficacy, this recommendation is particularly true for 
calcipotriol. 
•    The application of tacalcitol is particularly recommended 
for sensitive areas (e.g. face), owing to its low irritation 
potential.
•    In the first weeks, combined use together with topical 
corticosteroids or as a fixed combination is superior to 
monotherapy with respect to efficacy and tolerance. 
•    For moderate to severe psoriasis, a combination of 
topical vitamin D3 analogues with UV phototherapy or as 
systemic therapy can be recommended.
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examination, paying special attention to melanocytic naevi 
(especially if dysplastic) and cutaneous malignancies.
•    The patient must be informed about unwanted side-effects 
and possible long-term risks – especially the therapy-related 
increased risk of skin cancer. Additional UV exposure as a 
result of leisure-time activities should be considered.
•    Before starting oral PUVA therapy, an ophthalmological 
examination and the prescription of UV sunglasses is 
required.
During treatment
•    The UV dosages applied must be documented in precise 
physical units (J/cm2 or mJ/cm2). Regular monitoring of 
UV erythema must be performed for the purpose of dosage 
increases.
•    The medical records should document therapeutic response, 
unwanted side-effects, and accompanying treatments.
•    Eye protection with UV glasses is generally required.
•    If the areas chronically exposed to light (face, neck, backs 
of hands) and the genital region are free of lesions, these 
should be protected from exposure.
•    Adequate protection from the sun must accompany therapy.
Post-treatment
•    Whenever a course of therapy is completed, the cumulative 
UV dosage and the number of treatments should be 
recorded and the patient informed.
•    Particularly in the case of patients with high cumulative 
UV dosage, regular skin cancer examinations should be 
performed for the rest of the patient’s life.
Table XVI. Overview of phototherapy33
 Phototherapy
  UVB        +++               2     +++       Not indicated   +/-         +           ++
  
 PUVA 
     +++ to  
             2  
     +* 
      Not indicated      -      +/-           ++
         ++++      ++†
 
Global consideration:  poor ←-----------------------------------------→ good
              -      +/-        +        ++       +++      ++++
*Systemic PUVA.
†Bath/cream PUVA.
For notes on the definitions of the various parameters, please refer to the bottom of Table X. 
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Table XVII. Summary, phototherapy   
Recommended control parameters     Regular skin inspection (UV erythema)
Recommended initial dosage       Individual dose depends on skin type; options:
        •   UVB: 70% of minimum erythema dose (MED)
        •    Oral PUVA (photochemotherapy): 75% of the 
minimum phototoxic dose (MPD)
        •   Bath/cream PUVA: 20 - 30% of MPD
Recommended maintenance dosage     Increase according to degree of UV erythema
Expected beginning of clinical effect     After 1 - 2 weeks
Response rate       In >75% of the patients PASI-75% after 4 - 6 weeks (LE 2)
Important contraindications       Photo-dermatoses/photosensitive diseases, skin 
malignancies, immunosuppression
Important adverse reactions      Erythema, itching, blistering, malignancies
        Only oral PUVA: nausea
Important drug interactions      Drugs causing phototoxicity or photo-allergy
Other         In combination with topical preparations, acts 
synergistically; PUVA may not be combined with 
ciclosporin
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7.3 Excimer laser
•    Excimer laser is recommended for the targeted treatment of 
individual psoriatic plaques only. 
•    The 308 nm excimer laser can be administered to precisely 
targeted diseased skin, leaving healthy skin unexposed. 
•    The cumulative UVB dosage is therefore lower than 
conventional UV treatment.
•    Practicality is limited as a result of financial aspects as well 
as time resources on the part of the patient and physician. 
7.4 Systemic therapy
The recommendations in these guidelines will be presented 
according to the level of evidence (Table XVIII) and grade 
of recommendation (Table XIX) currently available for each 
systemic agent. The symbols used to indicate these are 
explained in the above tables.
7.4.1 Acitretin (oral retinoids) (Table XX) 
Background
Vitamin A (retinol) and its derivatives (retinoids) modulate 
keratinocyte differentiation and proliferation, but the exact 
mechanism of action in psoriasis has not been fully elucidated. 
Early use of retinoids involved supra-physiological dosing with 
vitamin A, causing hypervitaminosis A syndrome. Synthetic 
retinoids, etretinate (Tigason®) and acitretin (Neotigason®) were 
developed to overcome this side-effect. Acitretin is the only 
product currently available in South Africa for use in psoriasis 
and the only one included in these guidelines. Isotretinoin 
(Roaccutane®, Oratane®), used for acne treatment, is much less 
effective for psoriasis than acitretin. Retinoids are teratogenic 
and hepatotoxic but not immunosuppressant.35 
Evidence of efficacy
Plaque psoriasis 
A systematic review36 revealed 11 randomised controlled trials 
(RCTs) in which acitretin was used to induce remission and/or 
remission maintenance for psoriasis. The heterogeneous nature 
of the data made data pooling and analysis difficult. Despite 
its teratogenicity and the high incidence of symptomatic 
mucocutaneous side-effects, it was moderately effective as 
monotherapy at doses of 1 mg/kg/d (75 mg/d) compared 
with placebo, but was less effective than ciclosporin. Used in 
combination with PUVA, acitretin was more effective than 
monotherapy. There was insufficient evidence on the use of 
retinoids as long-term maintenance therapy.
A later evidence-based review37 included 5 reports on 
acitretin as monotherapy and confirmed that acitretin was 
superior to placebo at 1 mg/kg/d (75 mg/d), but 2 RCTs 
involving 286 people indicated that retinoids were less effective 
than ciclosporin at inducing remission in 10 - 12 weeks. 
Combination therapies were more effective than monotherapy. 
In combination with PUVA (6 series; N=286) acitretin combined 
Table XVIII. Levels of evidence  
1++   High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with very low risk of bias
1+    Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with low risk of bias
1-     Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++    High-quality systematic reviews of case-control or cohort studies; high-quality case-control or cohort studies with a very low 
risk of confounding, bias or chance and a high probability that the relationship is causal
2+     Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that 
the relationship is causal   
2-   Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not 
causal
3   Non-analytical studies, e.g. case reports, case series
4   Expert opinion
Table XIX. Grades of recommendation  
A  At least one meta-analysis, systematic review or RCT rated as 1++ and directly applicable to the target population; or a 
systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target 
population and demonstrating overall consistency of results
B  A body of evidence including studies rated as 2++, directly applicable to the target population and demonstrating overall 
consistency of results; or extrapolated evidence from studies rated as 1++ or 1+
C  A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall 
consistency of results; or extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+
0 Not recommendable
Therapeutic recommendation
•    Phototherapy is recommended as an induction therapy 
for moderate to severe psoriasis, particularly for 
widespread involvement. 
•    The side-effects of specific types of radiation must be 
weighed up. A possible subsequent risk of skin cancer is 
better documented for PUVA than for UVB.
•    Practicality and the association of long-term unwanted 
side-effects with cumulative UV doses must be taken 
into account in long-term treatment. Combination with 
topical vitamin D3 analogues is recommended to improve 
the response rate.
•    A recommendation for the common combination with 
tar, dithranol and corticosteroids can only be given on 
the basis of clinical experience, but not on the basis of 
scientific data.
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with PUVA (rePUVA) was marginally more effective than 
PUVA alone, and there was a trend for a lower accumulative 
UVA dose with the combination. Similar findings were shown 
for the UVB combination (3 RCTs; N=149) compared with 
UVB alone. In combination with topical corticosteroids (2 
series; N=160) and topical calcipotriol (2 studies; N=221), 
the combination was more effective than monotherapy with 
acitretin.  
The German evidence-based guidelines33 had only 4 studies 
meeting inclusion criteria for monotherapy and 4 studies for 
combination therapy. They concluded that the evidence for 
the effectiveness of acitretin as combination or monotherapy 
was poor owing to heterogeneous study results and do not 
recommend its routine use. 
Retinoids may be less effective than other systemic agents 
as monotherapy for short-term management of moderate to 
severe chronic plaque psoriasis, but they are effectively used in 
combination with phototherapy and topical agents or for long-
term maintenance of clearance induced with other agents.35,38 
Clinical data suggest that retinoids are effective for 
erythrodermic psoriasis control.35,38,39 Acitretin should 
be considered for those patients with co-morbidities 
contraindicating immunosuppression, such as cancer and HIV 
co-infection, as it is not an immunosuppressant.35 
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis 
interventions found established but modest evidence to 
support the use of oral retinoid monotherapy for the induction 
and maintenance of remission. Efficacy was equal to that of 
oral PUVA. Combined oral retinoid and PUVA (rePUVA) was 
more effective than either intervention used alone.40 
Psoriatic arthropathy
Effectiveness for psoriatic arthritis, compared with placebo, 
has been shown in one small trial summarised in a systematic 
review.41 
Adverse effects
Acitretin use is associated with a large number of side-effects 
and toxicity reactions (Table XX). Compared with other 
systemic interventions for severe psoriasis, the potential for 
serious harm appears to be less.35,38,39 
Table XX. Summary, acitretin (1- ; C)
Recommended control parameters   Pregnancy testing, contraception use, plasma lipids, transaminases and skeletal X-rays
Recommended dosage    Individual dosing dependent on the results, tolerability and concomitant medications 
used
     1 mg/kg/d to a maximum of 75 mg/kg/d
Efficacy     Monotherapy
      More effective than placebo but less effective than ciclosporin (at a dose of 75 mg/d)36 
     Combination therapy37 
     •   More effective in combination with PUVA than PUVA alone
     •   More effective in combination with UVB than UVB alone
     •    More effective than acitretin alone when used in combination with corticosteroids or 
calcipotriol
      Effective for erythrodermic and pustular psoriasis40 
     May be effective for psoriatic arthritis41 
     Consider in immunosuppressed (cancer or HIV) patients35 
Important contraindications   Teratogenicity
     A teratogen (category X) for women of childbearing age
      Because of its long half-life, contraception must be used for a minimum of 2 years after 
discontinuing its use
Important adverse reactions   Mucocutaneous side-effects
      These occur in most patients taking acitretin (they are features of hypervitaminosis A, 
and are dose-dependent and reversible)
     Most common: dry mucosa, alopecia, skin peeling, dermatitis 
     Less common: Paronychia, skin stickiness and skin and nail fragility 
     Liver dysfunction and musculoskeletal adverse effects 
     •    Increased triglycerides can be noted in up to 25% of patients and need to be 
monitored 
     •    Hepatotoxicity is rare, minor or transient elevation of transaminases may be 
documented more commonly
     •   Arthralgias and myalgias may occur
     •   With long-term use bone toxicity has been described 
Important drug interactions    Methotrexate (hepatotoxin), tetracyclines (pseudotumour cerebri), vitamin A 
supplementation (hypervitaminosis A syndrome), alcohol, phenytoin, progestin-only 
contraceptive pill, glibenclamide38,42 
Level of evidence    1-
Strength of recommendation   C
Other      Contraception must be used for a minimum of 2 years after discontinuation of acitretin 
in female patients of childbearing age 
      No blood donations should be made during and for a minimum of 2 years after 
stopping acitretin use
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7.4.2 Ciclosporin (Table XXI)
Background
Ciclosporin (Sandimmun®) is a calcineurin phosphatase 
antagonist and inhibits T-cell activation. A direct effect 
on keratinocytes has also been suggested. It is an 
immunosuppressant with significant renal toxicity, but is not 
teratogenic or myelosuppressant.35,36
Evidence of efficacy
Plaque psoriasis
A systematic review36 included 18 RCTs for ciclosporin 
remission induction efficacy (13 reports) and maintenance 
of remission efficacy (5 reports) for severe plaque psoriasis. 
The data were too heterogeneous for pooling (severity, dose, 
success criteria and duration of treatment), but favoured 
ciclosporin over placebo. Optimal remission induction 
responses were found for doses of 2.5 - 5.0 mg/kg/d, but 
higher doses, although more efficacious, were associated with 
more side-effects. The formulation (Sandimmun® v. Neoral®) 
did not affect efficacy in the long term, but the emulsion 
produced a more rapid initial response. Doses of 3.0 - 3.5 
mg/kg/d given continuously were needed for maintenance 
of remission. Comparative studies showed that low-dose 
ciclosporin was more effective than low-dose retinoids. 
Combined with calcipotriol, efficacy was enhanced.
A later systematic review43 included an additional RCT 
comparing ciclosporin and methotrexate as a monotherapy for 
moderate to severe plaque psoriasis, which is reviewed below. 
Recently published RCTs have compared monotherapy 
ciclosporin with methotrexate44-46 in moderate to severe plaque 
Therapeutic recommendation
•    Despite the poor recommendation as short-term 
monotherapy for chronic plaque psoriasis remission 
induction, acitretin is effective when used in combination 
with phototherapy and topical agents, or for the long-
term maintenance of remission/clearance induced by 
other systemic agents.
•    Acitretin is effective for the pustular and erythrodermic 
variants of psoriasis.
•   Acitretin may be effective for psoriatic arthritis.
•    Acitretin should be considered for those patients 
with co-morbidities where immunosuppression is 
contraindicated, such as those with cancer and HIV 
co-infection, as it is not an immunosuppressant.
•    Acitretin is a teratogen and is not recommended for 
women of childbearing age. Because of its long half-life, 
contraception must be used for a minimum of 2 years 
after stopping acitretin use, and no blood donations are 
possible for this time period either.
Table XXI. Summary, ciclosporin (1+; A)   
Recommended control parameters    General monitoring recommendations 
       Full blood count, liver and renal functions, blood pressure (reduce dose or 
use nifedipine), serum potassium, HIV, hepatitis B and C
      Renal monitoring recommendations48 
       Three baseline creatinine levels are recommended to calculate average pre-
treatment creatinine. Monitor weekly creatinine for increases in level from 
baseline. An increase of 30% (maximum) above average pre-treatment level 
should be accompanied by a decreased dose in ciclosporin. If increase persists 
discontinue ciclosporin to prevent irreversible renal damage
Recommended initial dosage    2.5 mg/kg/d36 
Recommended maintenance dosage    3.0 - 3.5 mg/kg/day36 
      Interval therapy dosing has been recommended to limit adverse effects
Efficacy        Effective remission induction therapy in all types of psoriasis
      Effective in moderate to severe plaque psoriasis and psoriatic arthritis
      Improves but does not clear palmoplantar pustulosis
Important contraindications    Hypertension, renal disease, active chronic infections
      History of malignancy 
      Pregnancy risk (category C)
Important adverse reactions     Major toxic effects are hypertension, nephrotoxicity and immunosuppression
       Other side-effects include myalgia, arthralgia, nausea, diarrhoea, headache, 
gingival hyperplasia, paraesthesiae, tremor and hypertrichosis 
Important drug interactions36,42    Inducers of cytochrome P450 3A
       Anticonvulsants (phenytoin, carbamazepine, phenobarbitone), rifampicin, 
sulphonamides
      Inhibitors or substrates of cytochrome P450 3A
      Macrolides, metronidazole, azoles, protease inhibitors, calcium channel  
      blockers (diltiazem, verapamil, nicardipine), selective serotonin reuptake  
      inhibitors, prednisone, grapefruit 
      Potentiate renal toxicity
      Aminoglycosides, NSAIDs, vancomycin
Level of evidence     1+
Strength of recommendation    A
Other       Increased risk of squamous cell carcinoma especially in those predisposed 
(skin phototype, previous sun damage, previous immunosuppressive 
therapy)
      Increased risk of lymphoproliferative diseases in transplant patients33
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psoriasis. Both ciclosporin (3 - 4 mg/kg/d) and methotrexate 
(0.5 mg/kg/wk) were shown to be effective in a study from 
India (N=30), but methotrexate appeared to produce more 
rapid and complete clearance. Side-effects were transient 
and minor.44 In contrast, there was no difference in efficacy, 
tolerability, rate of remission, time to remission or quality 
of life score in a study from the Netherlands (N=88). Both 
ciclosporin (3 - 5 mg/kg/d) and methotrexate (15 - 22.5  
mg/wk given as 3 doses every 12 hours) over 16 weeks 
resulted in a reduction in psoriasis severity index from baseline 
of ≥75% (PASI-75) in more than 60% of the patients.45 In 
contrast, a study from Sweden (N=84) showed a 72% reduction 
in PASI (PASI-75 = 58%) for ciclosporin (3 - 5 mg/kg/d) 
compared with a 58% reduction in PASI (PASI-75 = 24%) for 
methotrexate (7.5 - 15 mg/wk given as 3 doses every 12 hours 
with folate 5 mg/d on non-treatment days) over 12 weeks. 
There was no difference in quality of life and side-effects were 
common but tolerable. Although both drugs were effective, 
ciclosporin was more effective in the short-term treatment of 
moderate to severe chronic plaque psoriasis.46  
The German guidelines33 had 15 studies meeting inclusion 
criteria for monotherapy. They concluded that there is good 
evidence and an acceptable risk/benefit ratio for ciclosporin 
as effective monotherapy for remission induction of moderate 
to severe plaque psoriasis, but advised caution with long-term 
use because of the renal side-effects.
A systematic review and meta-analysis of RCTs evaluating 
the efficacy (PASI-75) and tolerability (overall rate of 
withdrawal) of systemic treatments for moderate to severe 
psoriasis from Europe and North America, found 9 trials for 
ciclosporin meeting inclusion criteria.47 The response (PASI-75) 
ranged from 25% to 97%, and the variability was only partly 
explained by variable dosing. Open-label studies had more 
patients reaching PASI-75 than did double-blind placebo-
controlled trials. Ciclosporin (71.4% PASI-75) was more 
effective than methotrexate (60.5% PASI-75) after 16 weeks of 
treatment. Long-term efficacy (stable responses for >10 months) 
was reported in only one study. Owing to heterogeneity 
associated with an overestimation of efficacy in open-label 
studies, only double-blind placebo-controlled trials (3/9) of 
ciclosporin were included in the meta-analysis of 16 studies 
for biologicals. Ciclosporin (absolute risk difference (RD) 
33%, 95% confidence interval (CI) 13 - 52%) was less effective 
than infliximab (RD 77%, 95% CI 72 - 81%), adalimumab (RD 
64%, 95% CI 61 - 68%) and high-dose (50 mg twice weekly) 
etanercept (RD 44%, 95% CI 40 - 48%), but equivalent to or 
better than low-dose (25 mg twice weekly) etanercept (RD 30%, 
95% CI 25 - 35%) and efalizumab (RD 24%, 95% CI 19 - 30%). 
Tolerability of ciclosporin was equivalent to the biologicals but 
better than methotrexate. 
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis 
interventions found 2 trials for ciclosporin.40 Despite 
heterogeneous data, the authors concluded that there was good 
evidence for improvement, but not clearance, with short-term, 
low-dose ciclosporin use.
Psoriatic arthropathy
In a systematic review of psoriatic arthropathy interventions, 
no RCTs were available to evaluate the use of ciclosporin.41 
Adverse effects
Ciclosporin is metabolised in the liver, so bio-availability and 
plasma levels are altered by drugs affecting the cytochrome 
P450 3A enzyme system.
Ciclosporin use is associated with a large number of side-
effects and toxicity reactions because of its narrow therapeutic 
index, low threshold for toxicity and plasma levels which 
are easily affected by inducers, inhibitors and substrates of 
cytochrome P450 3A.33,36,38,42,43 The incidence and severity of 
side-effects seen in patients with psoriasis correlates with the 
cumulative dose and/or duration of use.37
7.4.3 Methotrexate (Table XXII)
Background
Methotrexate (P & U Methotrexate®, Emthexate®, Abitrexate®), 
a folic acid antagonist, is an anti-metabolite, which inhibits 
dihydrofolate reductase preventing nucleotide synthesis, 
nucleic acid synthesis and hence cell proliferation. Its 
mechanism of action in psoriasis is unknown. It was thought 
to have a direct effect on keratinocyte proliferation, but 
current views link it to T-cell function. It is hepatotoxic, 
myelosuppressant and teratogenic.35 
Evidence of efficacy
Plaque psoriasis
A systematic review36 revealed no randomised controlled trials 
(RCTs) in which methotrexate efficacy could be evaluated, 
despite its widespread use and supporting published studies 
suggesting a significant effect. A later systematic review of 
treatments for moderate and severe plaque psoriasis43 included 
2 RCTs for methotrexate as monotherapy, which are reviewed 
below. Published RCTs have compared methotrexate with 
ciclosporin44 -46 or adalimumab49 and placebo41,49 in moderate to 
severe plaque psoriasis. 
Therapeutic recommendation
•    Ciclosporin is effective remission induction therapy for 
all types of psoriasis.
•    Ciclosporin has equivalent but varying efficacy compared 
with methotrexate, dependent on the population and 
dose studied and the use of folate supplementation. 
•    Ciclosporin has been shown to be effective for moderate 
to severe plaque psoriasis when used at doses of 2.5 - 5 
mg/kg/d. 
•    Ciclosporin improves but does not clear palmoplantar 
pustulosis.
•    Common use confirms its effectiveness for psoriatic 
arthritis.
•    Ciclosporin use is limited by the side-effect, drug 
interaction and contraindication profiles and monitoring 
required while on use. 
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Both methotrexate (0.5 mg/kg/wk) and ciclosporin (3 - 4 
mg/kg/d) were found to be effective in a study from India 
(N=30), but methotrexate appeared to produce a more rapid 
and complete clearance. Side-effects were transient and minor.44 
In contrast, there was no difference in efficacy, tolerability, 
rate of remission, time to remission or quality of life score in 
a study from the Netherlands (N=88). Both methotrexate (15 - 
22.5 mg/wk given as 3 doses every 12 hours) and ciclosporin (3 
- 5 mg/kg/d) over 16 weeks resulted in a reduction in psoriasis 
severity index from baseline of ≥75% (PASI ≥75) in more than 
60% of the patients.45 A study from Sweden (N=68) showed 
a 58% reduction in PASI (PASI-75 = 24%) for methotrexate 
(7.5 - 15 mg/wk given as 3 doses every 12 hours with folate 5 
mg/d on non-treatment days), compared with a 72% reduction 
(PASI-75 = 58%) for ciclosporin (3 - 5 mg/kg/d) over 12 weeks. 
There was no difference in quality of life and side-effects were 
common but tolerable. Although both drugs were effective, 
ciclosporin was more effective in the short-term treatment of 
moderate to severe chronic plaque psoriasis.46  
In an international randomised, double-blind, double-
dummy, placebo-controlled study (Canadian and European 
cohort N=271), a patient response rate of PASI-75 was achieved 
in 79.6% of patients given adalimumab (80 mg subcutaneously 
week 0 then 40 mg every 2 weeks), 35.5% of those given 
methotrexate (7.5 - 25 mg/week orally) and 18.9% of those 
receiving placebo for 16 weeks. All patients received 5 mg 
folate weekly, 48 hours after oral medication (CHAMPION 
study).49 Methotrexate dose, treatment duration and the use of 
folate could explain the different responses recorded above. 
Placebo comparisons include the CHAMPION study49 and 
an RCT of methotrexate use for psoriatic arthritis.41 In 37 
patients receiving methotrexate (7.5 - 15 mg/wk orally) or 
placebo for 12 weeks, a reduction in psoriasis surface area was 
noted for methotrexate compared with placebo. 
The German guidelines33 had only 3 studies meeting 
inclusion criteria for monotherapy. They concluded that 
methotrexate as monotherapy was effective for moderate to 
severe plaque psoriasis despite the lack of definitive studies, 
but its use was limited by the controls needed during therapy 
and contraindications. It was not recommended for remission 
induction owing to its slow onset of action.
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis 
interventions found no trials for methotrexate.40
Psoriatic arthropathy
Although widely accepted as effective, methotrexate has 
been shown to be effective for psoriatic arthritis in only 
one study using high doses administered parenterally in a 
systematic review of psoriatic arthropathy interventions. 
There is inconclusive evidence for the use of low-dose oral 
methotrexate.41 
Adverse effects
Methotrexate use is associated with a large number of side-
effects and toxicity reactions.43 Excretion is via the kidney and 
drug levels are therefore affected by renal function (Table XXII). 
Table XXII. Summary, methotrexate (1-; B)   
Recommended control parameters    Pregnancy testing (category X), contraception use, full blood count, liver and 
renal function, chest X-ray, hepatitis serology, HIV
       Liver biopsy is indicated in patients at risk for liver fibrosis (diabetes, 
overmass, history of liver problem, total dose >1.5 g) when methotrexate is 
used for prolonged periods as maintenance therapy
Recommended dosage    5 - 25 mg/wk 
Efficacy       Effective for chronic moderate to severe plaque psoriasis
      Lack of evidence in palmoplantar pustular psoriasis
      May be effective in psoriatic arthritis
Important contraindications     Alcohol use, impaired liver function, immunodeficiency, breastfeeding and 
pregnancy (both male and female patients considering pregnancy; category 
X) 
Important adverse reactions    Major toxic effects 
       Myelosuppression (often acute), hepatotoxicity, pneumonitis, gastro-intestinal 
ulceration and fetal abnormalities
      Common side-effects include
      Tiredness, nausea, anorexia, headache and alopecia
Acute toxicity management     Leucovorin (folinic acid) rescue: 20 mg folinic acid to be given parenterally 
within 48 hours of last dose. Repeat 6-hourly parenterally or orally as 
tolerated until methotrexate levels below toxic range
Important drug interactions (limited selection)   Drugs increasing methotrexate toxicity, especially myelosuppression
       Sulphonamides, trimethoprim, phenytoin, barbiturates (increase antifolate 
effect)33,38,42 
       Salicylic acid, NSAIDs, probenicid, penicillin, ciclosporin (decrease 
metabolism, or renal excretion or displace protein binding)33,38,42 
      Drugs increasing methotrexate toxicity, especially hepatotoxicity
      Ethanol, retinoids, NSAIDs33,38,42 
Level of evidence     1-
Strength of recommendation    B
Other      Consistent avoidance of alcohol
      No blood donations are possible for the period of use 
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Folic acid supplementation
The use of folate supplementation to reduce side-effects is 
controversial. A systematic review of its use in rheumatoid 
arthritis (RA) could not show any benefit owing to lack 
of uniformity of outcome measures, but did support the 
protective effects of folate for gastro-intestinal tract (GIT) 
and mucosal side-effect reduction. The dose of folic acid or 
folinic acid did not appear to matter.50 A recent randomised 
placebo-controlled study in RA patients (N=454) showed 
folate supplementation to be protective for hepatotoxicity 
compared with placebo, but it had no effect on GIT or mucosal 
symptoms.51 Folate supplementation has been shown to 
compromise methotrexate efficacy.52,53 Concomitant use of 
folate increased the total dose of methotrexate necessary to 
achieve the same response when compared with methotrexate 
alone.51,53 
7.5 Alternative systemic therapies
Alternative systemic agents sometimes used for recalcitrant 
psoriasis management include hydroxyurea, sulfasalazine, 
azathioprine, mycophenolate mofetil, fumaric acid esters, 
6-thioguanine and leflunomide. Only those that are available in 
South Africa for which there is supportive published evidence 
of efficacy from RCTs are included.
7.5.1 Hydroxyurea/hydroxycarbamide (Table XXIII)
Background
Hydroxyurea (Hydrea®) is cytotoxic, inhibiting DNA synthesis. 
Its mechanism of action is unknown in psoriasis. It suppresses 
the bone marrow and is best regarded as teratogenic, but is not 
nephrotoxic or significantly hepatotoxic.54,55 
Hydroxyurea has been proposed as a treatment for HIV 
because it inhibits DNA synthesis and causes cell cycle arrest 
and has favourable toxicity and drug interaction profiles. 
Laboratory work has shown that it blocks HIV transcription 
and/or replication and acts synergistically with didanosine in 
this regard.56
Evidence of efficacy
Plaque psoriasis
A systematic review36 reported one small RCT in which 
hydroxyurea (0.5 g twice daily) was compared with placebo 
in 10 patients with severe psoriasis in a 2×4-week cross-over 
Table XXIII. Summary, hydroxyurea [1-; C]
Recommended control parameters    Pregnancy testing (category X), contraception use, full blood count, liver and 
renal functions, malignancies
Recommended dosage    0.5 -1 mg/d for recalcitrant psoriasis
Response rate      >60% achieve 60 - 80% clearance,54,55 open-label case series
      PASI-75 in 53%; PASI-90 in 16% (open-label study)57 
Efficacy      Effective for recalcitrant psoriasis
       Lack of published evidence to support efficacy of hydroxyurea for 
palmoplantar psoriasis
       Lack of published evidence to support efficacy of hydroxyurea for psoriatic 
arthritis
      May have a role in the treatment of HIV-affected patients 
Important adverse reactions     Use is associated with bone marrow suppression and the side-effects may 
develop months after starting treatment54,55 
       Macrocytosis is common and not necessarily associated with anaemia – 
may be seen within 24 hours of the first dose and is a good indicator of 
compliance55,57 
       Mucocutaneous side-effects: alopecia, skin, hair and nail discoloration, 
painful lower leg ulceration, dermatomysitis and drug-induced lupus (long-
term use)54,55
      There is a risk of malignancies (cutaneous, leukaemia transformation)54,55
Acute toxicity       Acute mucocutaneous toxicity causes intense acral erythema and oedema, 
generalised pigmentation and stomatitis54,55,57 
Important drug interactions    Predominantly drugs causing myelosuppression 
Level of evidence     1-
Strength of recommendation    C
Therapeutic recommendation
•    Methotrexate is effective for chronic moderate to severe 
plaque psoriasis.
•   Methotrexate has been shown to:
•    Be effective for moderate to severe plaque psoriasis 
when used at doses of 7.5 - 25 mg/wk 
•    Have equivalent but varying efficacy compared with 
ciclosporin, dependent on the population and dose 
studied and the use of folate supplementation
•    Not be as effective as adalimumab and to cause more 
adverse events. 
•    There are no trials of methotrexate efficacy for 
palmoplantar pustular psoriasis.
•    Methotrexate may be effective for psoriatic arthritis.
•    Methotrexate use is limited by the side-effect and 
contraindication profile and monitoring required while 
on use. 
•    Folate supplementation may reduce hepatotoxicity 
side-effects in psoriatic patients, but can compromise 
methotrexate efficacy.
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study. Improvement was noted by both patients and doctors 
during periods of active therapy (9/10) compared with placebo 
(1/10). 
A review of the use of hydroxyurea for psoriasis55 identified 
a preliminary report of a small RCT comparing hydroxyurea (1 
g/d) with methotrexate (2.5 mg/d) in 8 patients in a 2×6-week 
cross-over study. Hydroxyurea was reported to be as effective 
as, or better than, methotrexate in 5/8 patients. 
Two open-label case series summarised in the British 
Association of Dermatology guidelines54 and the above 
review55 reported that >60% of the 60 and 85 patients treated 
with hydroxyurea, respectively, achieved a good or excellent 
response (38/60 achieved 60 - 80% clearance, 10/60 no 
response; 51/85 clear or almost clear, 6/80 no response). Doses 
of hydroxyurea and treatment period varied (1 g/d over 4 - 
12 weeks, repeated over 18 months; 0.5 g/d increased to 1.5 
g/d in poor responders over 4 - 36 months). Responses were 
seen within the first 6 weeks of therapy and the response 
was maintained on therapy. Remission was seen for all forms 
of psoriasis including pustular and erythrodermic psoriasis. 
Additional case series were identified in the review.55 In 
100 patients managed with hydroxyurea (1 g/d treated for 
variable periods over 8 years) a ‘worthwhile’ response was 
seen in 63/100 patients including the 18 ‘excellent’ responses. 
Two smaller series (20 and 16 patients) reported similar good 
response rates.
An open-label study of 31 chronic plaque psoriasis patients 
in India reported a good, but slow, response for hydroxyurea 
dosed at 1.0 g - 1.5 g/d. Treatment duration ranged from 6 
to 136 weeks. Good responses (70 - 90% reduction in PASI) 
were reported for 17/31 (53%) with complete or almost 
complete (>90% reduction in PASI) responses seen in 8/31 
(16%). Macrocytosis was seen in all patients by 2 weeks and all 
adverse effects were reported as mild and reversible.57 
The German guidelines did not include hydroxyurea.33
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis 
interventions found 1 small (13 patients), short, cross-over 
trial comparing hydroxyurea with placebo. There were no 
differences in the scores during the placebo and intervention 
period.40 
Psoriatic arthropathy
A systematic review of chronic psoriatic arthritis interventions 
found no trials for hydroxyurea efficacy that could be 
evaluated.41 
Adverse effects
Adverse effects of hydroxyurea are set out in Table XXIII.
7.5.2 Sulfasalazine (Table XXIV)
Background
Sulfasalazine (Salazopyrin®) is an anti-inflammatory agent 
used widely for treating inflammatory joint disease. It is split 
by intestinal bacteria into sulfapyridine and 5-aminosalicylic 
acid. Sulfapyridine is absorbed, metabolised in the liver and 
excreted in the kidney. The 5-aminosalicylic acid is excreted in 
the faeces. Its mechanism of action is unknown in psoriasis. It 
is potentially a bone marrow suppressant.36 
Evidence of efficacy
Plaque psoriasis
A systematic review36 revealed one small RCT in which 
sulfasalazine (3 - 4 g/d) was compared with placebo in 50 
patients with plaque psoriasis over 8 weeks. Improvement 
(>60%) was noted in 7/17 (41%) of those treated who were 
assessable, compared with none of those receiving placebo 
(0/27). Six of the original 23 patients withdrew because of side-
effects.
The British Association of Dermatologists53 and German 
guidelines33 did not include sulfasalazine.
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis 
interventions did not report any studies for sulfasalazine use.40 
Psoriatic arthropathy
A systematic review of chronic psoriatic arthritis interventions 
found 6 trials evaluating sulfasalazine efficacy meeting their 
criteria for inclusion.41 They conclude that there is good 
published efficacy for sulfasalazine use for treating psoriatic 
arthritis, despite a significant placebo response for the 
condition.
Adverse effects
Adverse effects are set out in Table XXIV. 
7.6 Biologicals
7.6.1 Overview and background information
Although effective, the conventional systemic drugs including 
methotrexate, ciclosporin and retinoids are associated with 
considerable toxicity that limits their long-term use. Recent 
developments in more targeted therapies involving biological 
Therapeutic recommendation
•    Hydroxyurea has been shown to be effective as a 
systemic agent at doses of 0.5 - 1.5 g/d for recalcitrant 
psoriasis. 
•    There is a lack of evidence to support efficacy of 
hydroxyurea for palmoplantar pustular psoriasis.
•    There are no trials of hydroxyurea use for psoriatic 
psoriasis.
•    Hydroxyurea may have a role in treating HIV-affected 
patients. 
•    Macrocytosis is commonly seen and a marker of 
compliance.
Therapeutic recommendation
•    There is little evidence to support the efficacy of 
sulfasalazine for psoriasis of the skin. 
•    Sulfasalazine may have a role in treating psoriasis 
patients with psoriatic arthritis. 
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agents, such as anti-T-cell agents and inhibitors of tumour 
necrosis factor-alpha (TNF-α), offer an alternative treatment 
approach with the possibility of longer continuous therapy, 
which may translate into disease control and improved quality 
of life.
Biological agents are proteins that can be extracted from 
animal tissue or produced by recombinant DNA technology 
and possess pharmacological activity.58 Biological therapies 
block specific molecular steps in the pathogenesis of psoriasis. 
Three types of molecules have been studied for use in psoriasis: 
•   recombinant human cytokines or growth factors
•   monoclonal antibodies
•   fusion proteins.
The nomenclature of biologicals has been standardised, and 
the suffix of the drug name helps with identification (Table 
XXV).
7.6.2 Strategies for biological therapy in psoriasis
Biologicals used to treat psoriasis target two key steps in the 
pathogenesis of the disease, namely either:
•    T-cell or antigen-presenting cell targeted (e.g. efaluzimab, 
alefacept), or
•    acting on TNF-α (e.g. adalumimab, etanercept, infliximab).
7.6.3 Considerations for biological therapy
In considering a patient for biological therapy, the following 
assessment tools are used:
•   PASI59  
•   DLQI58 
•   BSA affected.60 
The BSA is used where PASI is not applicable, e.g. in 
pustular psoriasis.
Eligibility criteria
To be considered for treatment, patients:
•   must have severe disease, and
•    must fulfil one of the clinical categories outlined in (ii) 
below.
(i) Definition of severe disease:
•   PASI score ≥10 
•   or BSA of ≥10% if PASI is not applicable
•   disease should be severe for more than 6 months
•   disease should be resistant to therapy
•   patient should be a candidate for systemic therapy.
In some circumstances, e.g. disabling acral disease, patients 
may fall outside this definition but may still be considered for 
treatment.
(ii) At least one of the following clinical categories must be 
fulfilled.
Patients who:
•    have developed or are at higher than average risk of 
developing clinically important drug-related toxicity and 
where alternative standard therapy cannot be used
•    are or have become intolerant to or cannot receive standard 
systemic therapy
•    are or have become unresponsive to standard therapy
•    have disease that is only controlled by repeated inpatient 
management
•    have significant, co-existent, unrelated co-morbidity that 
precludes use of systemic agents such as ciclosporin or 
methotrexate
•    have severe, unstable, life-threatening disease 
(erythroderma or pustular psoriasis)
Table XXIV. Summary, sulfasalazine (2; C)
Recommended control parameters    Pregnancy testing (category B risk), contraception use, full blood count, liver 
and renal function
Efficacy       Minimal published evidence to support sulfasalazine efficacy at doses of 3 - 4 
g/d for chronic plaque psoriasis in those who can tolerate it 
       Lack of published evidence to support efficacy of sulfasalazine for 
palmoplantar pustular psoriasis
       Well-documented published evidence that sulfasalazine is effective for 
psoriatic arthritis
Important adverse reactions     Sulfasalazine is not well tolerated owing to associated gastro-intestinal side- 
effects and headache
      Reversible oligospermia and infertility are relatively common
       Hepatotoxicity, haematological (binds iron, precipitates folate deficiency) and 
hypersensitivity reactions are described36 
Important drug interactions     Potentiates the action of drugs metabolised by the cytochrome P450 enzyme 
system
Level of evidence     2
Strength of recommendation    C
Table XXV. Nomenclature of the biologicals
-ximab    Chimeric monoclonal antibody (infliximab, rituximab, etc.)
-zumab    Humanised monoclonal antibody (efalizumab, etc.)
-umab    Human monoclonal antibody (adalimumab, etc.)
-cept    Receptor-antibody fusion protein (alefacept, etanercept, onercept, etc.)
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•    have psoriatic arthritis fulfilling the South African 
Rheumatology Society eligibility criteria for treatment with 
anti-TNF agents in association with skin disease.
Standard systemic therapy includes:
•   acitretin
•   ciclosporin
•   methotrexate
•   narrow-band ultraviolet (UV) B
•   PUVA.
Unresponsive to standard therapy is defined as an 
unsatisfactory clinical response (less than 50% improvement 
in baseline PASI score or percentage BSA where PASI is not 
applicable, and less than 5-point improvement in DLQI) to at 
least 3 months of treatment in the therapeutic dose range to the 
following treatments:
•    methotrexate single weekly dose (oral, subcutaneous, 
intramuscular) 15 mg, max. 25 - 30 mg
•   acitretin 25 - 50 mg/d
•   ciclosporin 2.5 - 5 mg/kg/d
•    narrow-band UVB or PUVA (non-response, rapid relapse 
or exceeding recommended maximum doses) 150 - 200 
treatments for PUVA and 350 treatments for narrow-band 
UVB.61 
A DLQI score of >10 correlates with a substantial effect on the 
patient’s quality of life.
Exclusion criteria for anti-TNF agents and efalizumab
•   Pregnant or breastfeeding.
•   Active infections. High risk includes the following: 
•   chronic leg ulcers
•   persistent or recurrent chest infections
•   indwelling urinary catheter
•   latent tuberculosis.*
•   Malignancy or premalignancy states excluding:
•   adequately treated non-melanoma skin cancer
•    malignancies diagnosed and treated more than 10 years 
previously. 
•   Demyelinating disease.*
•   Congestive cardiac failure.*
Relative contraindications
•    PUVA therapy >200 treatments, especially when followed 
by ciclosporin therapy
•   HIV positive or AIDS
•   hepatitis B or C.
Adequate response to treatment
This is defined as a 50% or greater reduction in baseline PASI 
score (or percentage BSA where PASI is not applicable) and a 
5-point or greater improvement in DLQI within 3 months of 
initiation of treatment.
Withdrawal of therapy
Therapy should be withdrawn if the criteria for adequate 
response have not been fulfilled in 3 months.
Who should prescribe biological therapy?
Treatment should be initiated and monitored (Table XXVI) by 
consultant dermatologists experienced in managing difficult 
psoriasis.
*These apply to anti-TNF agents only.
Table XXVI. Recommended pretreatment and monitoring investigations
       Pretreatment  Monitoring
Disease severity assessment
Skin 
PASI       Yes   3 months, then every 6 months
DLQI       Yes   3 months, then every 6 months
Joints – follow recommendations of  
SA Rheumatological Association    Yes   3 months, then every 6 months
General health (symptom enquiry and  
clinical examination)
Infection       Yes   3 - 6-month intervals
Demyelination      Yes   3 - 6-month intervals
Heart failure      Yes   3 - 6-month intervals
Malignancy (including skin)     Yes   3 - 6-month intervals
Assessment for latent tuberculosis (Fig. 2)
Blood tests
FBC       Yes    Efalizumab: monthly for first 3 
months, then every 3 months, anti-
TNF agents: 3 months, then every 6 
months
U+E, creatinine      Yes   3 months, then every 6 months
LFT       Yes   3 months, then every 6 months
Hepatitis B and C     Yes   -
HIV       Consider in patients at risk -
 Auto-antibodies (antinuclear antibodies,  
antidouble-stranded DNA antibodies)   Yes    -
Urine     Urinalysis Yes   3 months, then every 6 months
Radiology    CXR  Yes   -
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Fig. 2. Algorithm for assessment and management of tuberculosis (TB) in 
patients scheduled for anti-TNF therapy.62   
 
Group 1 
Abnormal CXR suggestive of TB or 
previous history of TB treatment 
Group 2 
Normal CXR and no history of prior 
TB 
On oral immunosuppressive 
therapy 
NO 
Had BCG? 
Tuberculin test 
(Mantoux or Heaf) 
Tuberculin test 
(Mantoux or Heaf) 
NO YES 
Heaf 2 - 4 
Mantoux 
<6 mm 
Heaf 0 - 1 
Mantoux 
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Heaf 0 - 2 
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Heaf 3 - 4 
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for TB risk 
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No further action 
YES 
Tuberculin test 
invalid. 
Assess risk 
REFER TO 
THORACIC 
PHYSICIAN 
Requires 
stratification for TB 
risk.   
Refer to thoracic 
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Comment: 
Tuberculin skin testing may be unreliable in patients who are immunocompromised. 
Clinical awareness of the possibility of TB should be maintained throughout anti-TNF therapy and for 6 months 
after cessation. 
A new diagnostic test that assays interferon-gamma to identify TB is not any better than the Mantoux test as 
neither is capable of differentiating between latent and active disease.95 
 
Adapted with permission 
from the British 
Association of 
Dermatologists 
Guidelines61  
Fig. 2. Algorithm for assessment and management of tuberculosis (TB) in patients scheduled for anti-TNF therapy.62  
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For the purposes of this section of the guideline, products are 
listed in their therapeutic class and in subsequent alphabetical 
order.
7.6.4 T-cell-targeted biologicals
7.6.4.1 Alefacept 
Alefacept (Amevive®; Biogen) was the first biological agent 
approved for treatment of psoriasis. Alefacept is a recombinant 
dimeric fusion protein. It binds to CD2 on the memory-effector 
T lymphocytes. The dose regimen, precautions and clinical 
response are summarised in Table XXVII.
General assessment
The efficacy of alefacept as induction therapy has been 
demonstrated in placebo-controlled studies, with 28% of 
patients achieving PASI-75 after a 12-week course (7.5 mg 
administered intravenously once weekly), rising to 40% 
in those patients receiving a second treatment course.63 
Intramuscular alefacept (10 or 15 mg once weekly) 
demonstrated PASI-75 in 28 - 33% of patients after 12 weeks. 
Data for longer treatment with alefacept are based on reports 
of repeated 12-week treatment courses.63 Follow-up data 
from both phase III studies showed that after one course of 
therapy, 29% of patients achieved PASI-75. Among patients 
who received at least two courses of alefacept, an incremental 
response was seen with 54% achieving PASI-75.63 For patients 
who responded, remission lasted an average of 7 months. 
Continuous treatment is not prescribed in clinical practice; 
rather, alefacept is given as intermittent 12-week treatment 
courses, either as monotherapy or in combination with other 
agents.63
Alefacept is generally well tolerated. Chills are 
occasionally experienced, particularly with IV administration 
and usually soon after dosing, and are often limited to one or 
two occasions during early treatment. It is necessary to monitor 
CD4+ cell counts before and during alefacept therapy,63 and the 
drug should be withheld if the CD4 count drops below 250 
cells/µl and discontinued if it remains below 250 cells/µl for 4 
consecutive weeks.64 However, randomised controlled studies 
do not reveal a higher incidence of infections and opportunistic 
infections. The rate of malignancies was similar to the control 
group.65  
7.6.4.2 Efalizumab
A press release dated 19 February 2009 released by the European 
Medicines agency reads as follows:
‘The European Medicines Agency (EMEA) has recommended the 
suspension of the marketing authorisation for Raptiva® (efalizumab), 
from Serono. The EMEA’s Committee for Medicinal Products for 
Human Use (CHMP) has concluded that the benefits of Raptiva® no 
longer outweigh its risks, because of safety concerns, including the 
occurrence of progressive multifocal leukoencephalopathy (PML) in 
patients taking the medicine.’ The FDA has withdrawn the drug since 
June 2009.67
7.6.5 Cytokine modulators: TNF-α blockers
7.6.5.1 Adalimumab
Adalimumab (Humira®, Abbott Laboratories) is the first anti-
TNF-α antibody that is entirely human in origin. In theory, 
antibody formation is less likely to occur. It is administered 
subcutaneously at a dose of 40 mg fortnightly, although it 
can be administered weekly, with or without methotrexate. 
The dosage regimen, precautions and clinical response are 
summarised in Table XXVIII.
In the UK adalimumab was licensed for the treatment of 
RA in September 2003. It is registered in South Africa for 
the treatment of psoriasis and psoriatic arthritis, and is also 
licensed for the treatment of other inflammatory conditions 
such as Crohn’s disease, RA and ankylosing spondylitis.68 
Early evidence indicated that PASI-75 can be achieved in 
53% of patients after 12 weeks’ treatment. More recent evidence 
shows that PASI-75 can be achieved in 71% of patients by 16 
weeks.69 
Recent published data, the first head-to-head trial evaluating 
the comparative efficacy of biological versus conventional 
systemic treatment for psoriasis, demonstrated significantly 
higher efficacy of adalimumab compared with methotrexate; 
80% of patients receiving adalimumab and 36% of patients 
receiving methotrexate achieved PASI-75 after 16 weeks.63 
Data for the treatment of RA suggest that adalimumab is as 
efficacious as infliximab or etanercept, but no head-to-head 
trials have been conducted.70 
Compared with other biological agents, longer-term efficacy 
data for adalimumab are more limited. In the larger phase 
Table XXVII. Summary, alefacept (1; A)
Recommended dose    15 mg IM (7.5 mg IV) weekly for 12 weeks 
Monitoring     CD4 T-cell count before treatment and weekly during treatment 
Side-effects     Some patients experience chills with the first injections
Expected beginning of clinical effect   Slow onset of action with apparent clinical improvement after 6 - 8 weeks  
Clinical response      PASI-75 after 12 or 24 weeks achieved by 14% and 28% of patients and 
respectively in 40% after a 2nd course.65,66 Often sustained remission. Prior 
response to alefacept is a likely marker of future treatment response; patients 
responding to the first course of therapy may therefore be treated long 
term with repeated 12-week courses of alefacept at a minimum of 24-week 
intervals13
       Improved outcome with second course of treatment and consistent benefit of 
repeated administration13
Level of evidence     113
Strength of recommendation    A13
Other       In phase II trials for psoriatic arthritis
Guideline
April 2010, Vol. 100, No. 4  SAMJ278
III study, among patients reaching PASI-75 after treatment 
with adalimumab, a loss of response was observed following 
re-randomisation to placebo, suggesting that continuous 
treatment is necessary to maintain a response.69 In this study, 
after 24 weeks of continuous treatment, 70% of patients 
achieved PASI-75, and at 33 weeks 89% achieved this response. 
However, PASI scores for longer treatment duration were not 
reported. 
In an open-label extension to the initial phase II study, in 
which 106 patients received continued treatment for 60 weeks, 
PASI-75 was achieved by 64% of patients receiving continuous 
weekly dosing and by 56% receiving adalimumab every other 
week.70 
Safety data for adalimumab in psoriasis are also limited 
compared with other biological agents. The most commonly 
reported adverse events in patients treated with adalimumab 
were nasopharyngitis, upper respiratory tract infection and 
headache. However, the incidence of severe adverse events was 
low and comparable in the adalimumab and placebo treatment 
groups. Until more data are available, the caveats for use of 
adalimumab should be considered to be the same as those for 
other TNF-α blockers.63 
7.6.5.2 Etanercept
Etanercept (Enbrel®, Wyeth Pharmaceuticals) is a fully human 
soluble recombinant p75 TNF receptor that blocks the binding 
of TNF to cell surface receptors, thereby neutralising its 
biological activity.
The dose regimen, precautions and clinical response are 
summarised in Table XXIX.
General assessment
Etanercept is registered in South Africa for the treatment 
of psoriasis and psoriatic arthritis. It is also licensed for the 
treatment of other inflammatory conditions such as RA, 
juvenile chronic arthritis and ankylosing spondylitis.71 
The recommended dose of etanercept for the treatment 
of psoriasis is 25 mg subcutaneously twice weekly by self-
administration, although this may be increased to 50 mg twice 
weekly. Etanercept may be given for up to 24 weeks. 
PASI-75 was achieved in up to 34% of patients after 12 
weeks of treatment with 25 mg subcutaneous etanercept twice 
weekly. Continuing treatment for 24 weeks further increased 
response. Doubling the dose to 50 mg twice weekly achieved 
PASI-75 in up to 49% of patients at 12 weeks.72,73 The median 
time to relapse after cessation of treatment was approximately 
3 months, with no rebound observed.
Etanercept treatment response has been found to be dose 
dependent, with a greater proportion of patients achieving 
PASI-75 with the 50 mg twice-weekly dosing regimen 
than with the 25 mg twice-weekly regimen over 12 weeks. 
Extending treatment to 24 weeks also improves response, 
with 44 - 45% of patients achieving PASI-75 with the 25 mg 
twice-weekly regimen, and 59% with the 50 mg twice-weekly 
regimen.63 
Longer-term data for up to 60 weeks of etanercept treatment 
have been reported in an open-label extension study of a phase 
III trial with treatment non-responders. At week 36, among 145 
patients, 12% had achieved PASI-75. At week 60 (N=112), 23% 
had achieved PASI-75. Another long-term, open-label extension 
study using etanercept 50 mg per week reported that, after 
initial efficacy at 12 weeks, 63% of patients who continued 
treatment reached PASI-75 at week 48. However, a modest 
reduction in response was seen with longer-term treatment, 
and at 96 weeks a PASI-75 response was seen in only 51% of 
patients.63
Table XXVIII. Summary, adalimumab (1; A)
Recommended dose    80 mg in the first week, 40 mg in the second week, followed by 40 mg every other 
week, given subcutaneously
Monitoring    Infection screen prior to treatment (NB: active or latent TB must be excluded)
Side-effects    Injection site reactions common
Expected beginning of clinical effect  Rapid onset of action69 
Clinical response    PASI-75 at 16 weeks achieved by 71%;69 64% by 60 weeks13
      Rebound typically does not occur, but clearance better maintained with continuous 
use13
Level of evidence    113
Strength of recommendation   A13
Other      Approved for the treatment of psoriatic arthritis and psoriasis
Table XXIX. Summary, etanercept (1; A)
Recommended dose   25 - 50 mg subcutaneously twice weekly for an indefinite period
Monitoring    Infection screen prior to treatment (NB: active or latent TB must be excluded)
Side-effects    Injection site reactions common
Expected beginning of clinical effect  Rapid onset within 2 - 3 weeks
Clinical response     PASI-75 at 12 weeks achieved by 34% (25 mg)/49% (50 mg);72,73 PASI-75 at 24 weeks 
45% (25 mg) and 59% (50 mg); PASI-75 at 60 weeks achieved by 23%13,72 ,73,75 
     Median time to relapse 3 months; relapse rates are variable
Level of evidence    113
Strength of recommendation   A13
Other      Approved for the treatment of psoriatic arthritis 
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Etanercept has been used in children aged 4 - 17 years with 
plaque psoriasis. Doses of 0.8 mg/kg to a maximum of 50 mg 
were given once weekly, and 57% achieved PASI-75 compared 
with 11% of those on placebo.74 
Etanercept has been well tolerated in clinical trials, apart 
from mild injection site reactions occurring in up to 36% of 
patients; these rarely led to discontinuation of treatment.75 
Neutralising antibody formation could not be observed. There 
are concerns about increased infection rates and a risk of 
malignancy associated with the use of etanercept. However, a 
safety review in RA showed a similar rate of serious infections 
for etanercept- and placebo-treated patients. No opportunistic 
infections were observed and the incidence of malignancies 
was similar to that expected.76 
7.6.5.3 Infliximab
Infliximab (Revellex® in South Africa/Remicade® 
internationally; Schering-Plough) is a monoclonal mouse/
human chimeric antibody that binds to TNF-α, thereby 
neutralising its activity. The dosage regimen, precautions and 
clinical response are summarised in Table XXX.
General assessment
Infliximab is registered in South Africa for the treatment of 
psoriasis and psoriatic arthritis. It is also licensed for the 
treatment of other inflammatory conditions such as Crohn’s 
disease in adults and children, ulcerative colitis, RA and 
ankylosing spondylitis.77
The efficacy of infliximab in psoriasis has been demonstrated 
in two phase II studies and a subsequent larger phase III 
study (EXPRESS study), involving a total of 660 patients, 
which found that treatment with infliximab (administered 
intravenously in doses of 3, 5 or 10 mg at weeks 0, 2 and 6) 
resulted in achievement of PASI-75 after 10 weeks in 70 - 80% 
of patients. Rapid clinical improvements were observed in all 
three studies.63,78 
Longer-term data from the EXPRESS study have been 
reported, with treatment continued (as an intravenous infusion 
of 5 mg/kg) at weeks 0, 2 and 6, and then every 8 weeks 
through to week 46. Of 271 patients receiving continued 
infliximab, a sustained response was observed at week 24, 
with 82% of patients attaining PASI-75, after which a moderate 
reduction in efficacy was noted, falling to 61% of patients 
reaching PASI-75 at week 50.63 
Similar findings were reported in a more recent comparison 
of continuous and intermittent infliximab therapy over 1 year, 
which involved an initial 835 patients.33 In an initial placebo-
controlled induction phase of this study, in the active treatment 
arm (intravenous infusions of 3 or 5 mg/kg) at weeks 0, 2 and 
6, PASI-75 was achieved in 70% (3 mg/kg) and 75% (5 mg/kg) 
of patients.63 
Patients were then randomised to receive continuous 
treatment (as intravenous infusions every 8 weeks) or 
intermittent ‘as-needed’ dosing (given when a PASI-75 
response was lost). With continuous therapy up to week 26, 
PASI-75 scores were maintained in 64% (3 mg/kg) and 78% 
(5 mg/kg) of patients. Subsequently, a reduced response to 
continuous 8-weekly infusion therapy was observed, with 
PASI-75 achieved by 44% of patients (3 mg/kg) and 54% of 
patients (5 mg/kg) at week 50. Patients receiving continuous 
dosing had consistently higher PASI-75 scores than those 
treated with intermittent dosing, and PASI scores were greater 
with the higher dose of infliximab.63
These data suggest that infliximab is effective as continuous 
treatment for up to 1 year, with some loss of response over 
time. Its benefits beyond this time frame are not known owing 
to the lack of longer-term data.63 
Infliximab has been well tolerated in clinical trials, with 
safety data available from over 1 million patients treated with 
the drug for various inflammatory conditions.79 
More commonly observed adverse events include headaches, 
nausea, upper respiratory infections and infusion reactions. 
Infusion reactions occurred in up to 16% of patients, but only 
2% discontinued the treatment because of the reactions.80 
There have been reports of new or worsening congestive 
cardiac failure in patients treated with infliximab and it should 
therefore be used with caution in patients with pre-existing 
cardiac failure.81 In a small number of patients with Crohn’s 
disease or RA, infections, antinuclear antibody formation and 
drug-induced auto-immune disease have been reported.82,83 
Patient-years of infliximab usage are associated with more 
reports of opportunistic infections, including tuberculosis, 
than other anti-TNF agents. There have also been rare 
reports of demyelinating disease.84 All patients considered 
for treatment with infliximab should be screened for active 
infection, in particular tuberculosis. There is currently no 
indication of higher rates of malignancy in patients treated 
with infliximab, but long-term data are not yet available. There 
Table XXX. Summary, infliximab (1; A)
Recommended dose   5 mg/kg IV (over 2 - 3 hours) at 0, 2 and 6 weeks (RA dose regimen) 
Monitoring    Infection screen prior to treatment (NB: active or latent TB must be excluded)
Side-effects    Infusion reactions are common
      Increased risk of infection, caution in congestive cardiac failure, demyelinating 
disorders
     Risk of antibody formation
Expected beginning of clinical effect  Rapid onset, within 1 week 
Clinical response     PASI-75 at 10 weeks achieved by >82%; 61% of patients achieved PASI-75 at week 
5013,63,78
Level of evidence    113
Strength of recommendation   A13
Other      Effective for psoriatic arthritis 
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is concern about an increased risk of lymphoma, particularly 
in patients with RA, who appear to be more susceptible.80 In 
patients with psoriasis who receive TNF-α blockers, long-term 
pharmacovigilance is required for skin cancer, as a significant 
number of these patients with severe disease will have also 
received photochemotherapy (PUVA).
7.6.6 Other cytokine modulators 
7.6.6.1 IL-12/23 monoclonal antibody (Ustekinumab)
Ustekinumab (Stelara®, Janssen Pharmaceuticals) is a fully 
human monoclonal antibody, which targets the p40 subunit of 
IL-12 and IL-23. The presumed mechanism of action is to block 
the binding of IL-12 and IL-23 to receptors on undifferentiated 
T cells, preventing differentiation/clonal expansion of 
pathogenic Th1 and Th17 populations and subsequent down-
regulation of inflammatory cytokines.85  
The dosage regimen, precautions and clinical response are 
summarised in Table XXXI.
General assessment
Members of the IL-12p40 family, namely IL-12 and IL-23, have 
been shown to play a pro-inflammatory role in psoriasis. They 
are produced by activated antigen-presenting cells and have 
been shown to increase interferon-gamma synthesis by T cells. 
IL-23 acts preferentially on interferon gamma production 
by memory T cells. IL-12 also increases differentiation of 
naive TH0 to TH1 cells and increases the cytolytic activity of 
activated T cells and NK cells.86
In the European Union, ustekinumab is indicated for the 
treatment of moderate to severe plaque psoriasis in adults who 
failed to respond to, have a contraindication to or are intolerant 
to other systemic therapies, including ciclosporin, methotrexate 
and PUVA.85 
In an open-label, phase I study of a single infusion of 
anti-IL12p40 (ustekinumab), PASI-75 was achieved by 67% 
of patients between 8 and 16 weeks after administration of 
the agent, and in the higher-dose group 100% of patients 
achieved PASI-75.87 A recent phase III trial (PHOENIX I) of the 
subcutaneous formulation in patients with moderate to severe 
psoriasis has demonstrated that 67.1% (45 mg) and 66.4% (90 
mg) of patients achieved PASI-75 at week 12. PASI-75 at week 
28 was 71.2% (45 mg) and 78.6% (90 mg).88 Recent evidence 
from another phase III study (PHOENIX II) in patients with 
moderate to severe psoriasis demonstrated a maintained 
treatment response at week 40, with between 58% and 67% of 
patients achieving PASI-75 at lower (45 mg) and higher (90 mg) 
dosages, respectively.89
Serious adverse events occurred in 4% of patients who 
received the monoclonal antibody and in 1% of those who 
received placebo. This study demonstrates the therapeutic 
efficacy of an IL-12/23 monoclonal antibody in psoriasis and 
provides evidence for a role of IL-12/23 in the pathophysiology 
of psoriasis.13 
A recent phase II study in patients with psoriatic arthritis, 
of whom 85% had associated skin psoriasis, showed that 
treatment with ustekinumab (90 mg or 63 mg) given weekly 
(weeks 0 - 3) followed by placebo at weeks 12 and 16, 
demonstrated an ACR 20 response of 42% for joint disease and 
a PASI-75 of 52% for skin disease. In this study ustekinumab 
treatment reduced the signs and symptoms of arthritis and 
associated psoriatic skin lesions, as well as significantly 
improving physical disability and quality of life in the majority 
of patients. This response was maintained in the majority of 
patients over week 36, after the last ustekinumab injection at 
week 3.90 No rebound response was reported in this study.90 
Infections such as tuberculosis are less likely with 
ustekinumab than with other biologicals, but latent infection 
should be actively excluded.
7.6.7 Comparative short-term efficacy of the biologicals
Two recent meta-analyses have been performed to summarise 
clinical trial efficacy data enabling a quantitative, indirect 
comparison between agents, as no current direct ‘head-to-head’ 
data between biological agents are available.47, 91 
In the first meta-analysis, 16 randomised, controlled, double-
blind, monotherapy trials of alefacept (N=3), efalizumab (N=5), 
Table XXXI. Ustekinumab (no data)
Recommended dose    The recommended initial dosage of ustekinumab is 45 mg administered subcutaneously 
at week 0, followed by a 45 mg dose at week 4, then every 12 weeks thereafter85 
      For patients with a body weight >100 kg the dose is 90 mg administered 
subcutaneously at week 0, followed by a 90 mg dose at week 4, then every 12 weeks 
thereafter 
      In patients weighing >100 kg, 45 mg was also shown to be efficacious. However, 90 mg 
resulted in greater efficacy in these patients85 
      Consideration should be given to discontinuing treatment in patients who have shown 
no response up to 28 weeks of treatment 
Monitoring    Infection screen prior to treatment (NB: active or latent TB must be excluded)
Side-effects    Injection site reactions are common85 
Expected beginning of clinical effect  Response expected by week 4
Clinical response     PASI-75 at 28 weeks achieved by 71.2% (45 mg)/78.6% (90 mg); PASI-75 at 40 weeks 
58% (45 mg) and 67% (90 mg)88 
     Median time to relapse is 15 weeks
Level of evidence    No data 
Strength of recommendation   No data
Other       Awaiting approval for moderate to severe plaque psoriasis 
     In development for psoriatic arthritis (phase II completed)
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etanercept (N=4) and infliximab (N=4), comprising  
7 931 patients, met inclusion criteria. Efficacy was measured 
by PASI-75 achievement after 10 - 14 weeks of treatment, 
using intention-to-treat analysis. All biological agents for 
psoriasis were efficacious (p<0.001); however, there was a 
graded response for achievement of PASI-75: infliximab 
(relative risk (RR)=17.40, number needed to treat (NNT)=2), 
etanercept (RR=11.73, NNT=3), efalizumab (RR=7.34, NNT=4) 
and alefacept (RR=3.70, NNT=8). At the same time, the risk of 
one or more adverse events was evaluated by RR and number 
needed to harm (NNH). This was increased in the alefacept 
(RR=1.09, p=0.03, NNH=15), efalizumab (RR=1.15, p<0.001, 
NNH=9) and infliximab (RR=1.18, p<0.001, NNH=9) groups 
compared with placebo.91 
In the second meta-analysis 24 RCTs totalling 9 384 patients 
were analysed qualitatively. Sixteen double-blind placebo-
controlled trials were eligible for meta-analysis. Efficacy was 
defined as proportion of participants who had achieved PASI-
75 at primary efficacy measurement (week 8 - 16). Infliximab 
was significantly superior to all other interventions (RD 77%, 
95% CI 72 - 81%). Adalimumab (RD 64%, 95% CI 61 - 68%) was 
superior to ciclosporin (RD 33%, 95% CI 13 - 52%), etanercept 
50 mg twice weekly (RD 44%, 95% CI 40 - 48%) and etanercept 
25 mg twice weekly (RD 30%, 95% CI 25 - 35%).47 
Additionally, a recent poster presentation of a phase III 
trial (ACCEPT) comparing the efficacy of ustekinumab and 
etanercept in moderate to severe psoriasis demonstrated that 
a significantly greater proportion of patients achieved PASI-75 
with ustekinumab 45 mg (67.5%, p=0.012) and 90 mg (73.8%, 
p<0.001) given at weeks 0 and 4 than with etanercept (56.8%) 
given as 50 mg twice weekly.92
Ustekinumab has also been compared in a meta-analysis 
versus the other biological treatments in a recent poster 
presentation. The estimated mean PASI-75 responses were as 
follows: infliximab (mean 80%, 95% CI 70 - 87%), ustekinumab 
90 mg (74%, 68 - 80%), ustekinumab 45 mg (69%, 62 - 75%), 
adalimumab (58%, 49 - 68%), etanercept 50 mg twice weekly 
(52%, 45 - 59%), etanercept 25 mg twice weekly (39%, 30 - 48%) 
and supportive care/placebo (4%, 3 - 4%).93  
7.6.8 Areas for future research
The main research gaps remain the great lack of key 
comparative data and of data concerning the long-term safety 
and efficacy of biological and non-biological treatments for 
moderate to severe psoriasis. Additionally, pragmatic head-
to-head RCTs lasting at least 2 years are needed to compare 
different biologicals with each other and with conventional 
systemic treatments for psoriasis. Because biologicals are 
currently recommended for patients who fail to respond to 
conventional systemic treatments, the comparative efficacy of 
biologicals in such a subgroup of treatment failures has to be 
assessed.63  
7.6.9 Choice of agents 
The choice of which of the biological agents to use is based on 
the clinical pattern of psoriasis, pre-existing co-morbidities, 
patient preference and local facilities.62  
A separate recommendation guideline for the use of 
biologicals in psoriasis is currently underway, and will further 
clarify the choice of biological agent, based on the most 
recently available research and clinical data. In the interim 
readers are requested to refer to the British Association of 
Dermatologists guidelines or consult the Dermatological 
Society of South Africa website. 
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